

1 **Title:** Endocytosis in *Trypanosoma cruzi* Depends on Proper Recruitment and Regulation of  
2 Functionally Redundant Myosin Motors

3  
4 **Keywords:** *Trypanosoma cruzi*, Cytostome, Cytopharynx, SPC, Myosin, MyoF, MyoC, Chagas  
5 Disease, American Trypanosomiasis, MyAP, Endocytosis, Phagocytosis, Reservosome

6  
7 **Authors:** Nathan M. Chasen<sup>1</sup>, Menna G. Etheridge<sup>1</sup>, Paul C. Campbell<sup>2</sup>, Christopher L. de  
8 Graffenried<sup>2</sup>, Kingsley Bimpeh<sup>3</sup>, Kelly M. Hines<sup>3</sup> and Ronald D. Etheridge<sup>1\*</sup>

9  
10 **Author Affiliations:**

11 1: Department of Cellular Biology, Center for Tropical and Emerging Global Diseases (CTEGD),  
12 University of Georgia, Athens, Georgia, USA.

13 2: Department of Molecular Microbiology and Immunology, Brown University, Providence,  
14 Rhode Island, USA.

15 3: Department of Chemistry, University of Georgia, Athens, Georgia, USA.

16 \* Corresponding Author: [ronald.etheridge@uga.edu](mailto:ronald.etheridge@uga.edu)

17  
18 **Email:**

19 Nathan M. Chasen: [nchasen@uga.edu](mailto:nchasen@uga.edu)

20 Menna G. Etheridge: [menna.etheridge@uga.edu](mailto:menna.etheridge@uga.edu)

21 Kingsley Bimpeh: [Familykingsley@uga.edu](mailto:Familykingsley@uga.edu)

22 Kelly M. Hines: [kelly.hines@uga.edu](mailto:kelly.hines@uga.edu)

23 Paul C. Campbell: [paul\\_campbell@brown.edu](mailto:paul_campbell@brown.edu)

24 Christopher L. de Graffenried: [christopher\\_degraffenried@brown.edu](mailto:christopher_degraffenried@brown.edu)

25  
26  
27 **Abstract:**

28 Utilized by the free-living kinetoplastid *Bodo saltans* to feed on bacterial prey, the cytotome-  
29 cytopharynx complex (SPC) is an endocytic organelle absent from all human trypanosomatid  
30 pathogens save *Trypanosoma cruzi*. Building upon our previous work identifying the myosin  
31 motor MyoF as the first enzymatic component of the *T. cruzi* SPC, we sought to expand our  
32 understanding of this distinct organelle by identifying additional protein machinery which  
33 contribute to the endocytic process. While deletion of MyoF alone did not fully ablate  
34 endocytosis, we found that deletion of both MyoF and the similarly localized MyoC produced an  
35 endocytic-null phenotype that was rescued upon complementation. To identify potential  
36 regulatory components of this motor complex, we pulled down MyoF and identified an SPC-  
37 targeted protein that contained an annotated EF-hand calcium-binding motif that was conserved  
38 across a wide range of protozoan lineages. Surprisingly, deletion of this myosin associated  
39 protein (MyAP) alone was sufficient to produce an endocytic-null phenotype, which we were  
40 able to fully rescue via complementation. The deletion of MyAP also caused the mis-localization  
41 of both cytopharynx myosins to the cytosol. While MyAP lacking the EF-hand domain was  
42 unable to complement endocytosis, it was sufficient to restore proper myosin localization. This  
43 suggested that MyAP plays two distinct roles, one in targeting myosins to the SPC and a  
44 second in regulating myosin motor activity. Transmission electron microscopy also revealed that  
45 endocytic-null mutants lacked the electron lucent lipid inclusions typically seen in the pre-  
46 lysosomal reservosomes of *T. cruzi* epimastigotes. Mass spectrometry based lipidomic analysis  
47 subsequently revealed a dramatic reduction in the scavenged cholesterol content in the  
48 endocytic-null mutants, which can be attributed to an inability to endocytose exogenous lipid-  
49 protein complexes for storage in the reservosomes. Overall, this work showcases the first viable

50 endocytic-null mutants generated in *T. cruzi* through specific gene deletion and highlights the  
51 feasibility of leveraging this strategy towards a full dissection of the endocytic machinery and  
52 biogenesis of the SPC.

### 53 **Importance:**

54 *Trypanosoma cruzi* chronically infects over 7 million people in the Americas and current  
55 therapeutics are insufficient to effectively cure infection. The lack of progress in developing  
56 effective vaccines or drug treatments is due, in part, to longstanding technical limitations in  
57 studying this parasite and a lack of resources committed to support research and eradication  
58 efforts. As part of its parasitic lifestyle, *T. cruzi* is forced to obtain basic nutrients directly from its  
59 host environment, making the development of methods to block nutrient uptake an attractive  
60 strategy to control parasite growth and transmission. While the bulk uptake of complex nutrients  
61 by *T. cruzi* occurs via an endocytic structure, often referred to as the cytotome-cytopharynx  
62 complex (SPC), how exactly this tubular endocytic organelle functions at a mechanistic level  
63 has remained a mystery. In this work, we investigated the contribution of several SPC targeted  
64 myosin motors and an associated protein factor to endocytic activity. By identifying and  
65 characterizing the molecular machinery responsible for nutrient uptake, we hope to both expand  
66 our basic understanding of how this deadly pathogen acquires essential nutrients from its host,  
67 while also revealing new potential therapeutic targets to impede nutrient uptake.

### 68 69 **Introduction:**

70 *Trypanosoma cruzi*, the etiological agent of Chagas disease, is a protozoan parasite that  
71 chronically infects upwards of 7 million people in the Americas resulting in an estimated 50,000  
72 deaths annually (1, 2). Unlike heavily studied salivarian trypanosomatids such as *Trypanosoma*  
73 *brucei* and *Leishmania spp.* which invade their human hosts directly through the proboscis of  
74 their hematophagous insect vectors, the stercorarian *Trypanosoma cruzi* is released in the  
75 feces of its blood feeding reduviid vector and must contaminate the bite wound or nearby  
76 mucosal membranes to infect its vertebrate host (3, 4). Over decades, chronic parasite infection  
77 can lead to the destruction of smooth and cardiac muscle tissue, ultimately manifesting as  
78 various mega viscera or cardiac disease in approximately 30% of those infected (5).  
79 Unfortunately, no effective vaccines are available to prevent infection and the chemical  
80 therapeutics currently in use are often toxic and ineffective against chronic infection (6, 7).  
81 Recent work has also highlighted parasite dormancy in the mammalian host as a potential  
82 mechanism by which *T. cruzi* may be able to resist clearance by the few chemotherapeutic  
83 options currently available, further supporting the need for a better understanding of this  
84 parasite's basic biology (8).

85  
86 One intriguing dimension of *T. cruzi*'s fundamental physiology which remains poorly understood  
87 is the mechanism by which the parasite acquires nutrients from its host environment. Unlike its  
88 salivarian cousins (*Trypanosoma brucei* and *Leishmania spp.*) which have repurposed their  
89 flagellar pocket membrane to be the sole location for endocytosis and exocytosis (9-11), *T. cruzi*  
90 utilizes an ancestral form of phagocytosis operating via a flagellar pocket adjacent organelle  
91 known as the cytotome-cytopharynx complex (SPC) which is still used by its free-living  
92 relatives (e.g. *Bodo saltans*) to capture and consume bacterial prey (reviewed in (12)). The SPC  
93 begins as an opening on the parasite surface (cytostome) and is followed by a dynamic tubular  
94 membrane invagination (cytopharynx) through which captured and endocytosed material is  
95 brought into the cell and ultimately digested (13). Connecting the opening of the flagellar pocket  
96 to the cytostome entrance is a unique cholesterol and glycan rich plasma membrane subdomain  
97 known as the pre-oral ridge (POR) that is compositionally distinct from the rest of the parasite  
98 surface membrane and originates at the base of the flagellar pocket via vesicular fusion. It is on  
99 this POR at the parasite surface that complex nutrients are thought to be captured by, as yet

100 unknown, membrane receptors prior to being drawn down into the SPC. The endocytic complex  
101 ultimately terminates with the budding of vesicles that are trafficked to the pre-lysosomal  
102 storage structures known as reservosomes to await digestion (14, 15). Undergirding this  
103 phagocytic structure are two sets of microtubule root fibers; one known as the cytostomal  
104 quartet (CyQ) which begins at the basal body, winds up the flagellar pocket and runs beneath  
105 the POR membrane before descending into the parasite body while the second rootlet known as  
106 the cytostomal triplet (CyT) originates adjacent to the cytostome opening itself and tracks  
107 alongside the CyQ forming a “gutter” within which lies the cytopharynx membrane tubule (16).  
108 Among single celled protozoans, these microtubule rootlets often facilitate the proper positioning  
109 and function of various subcellular organelles (reviewed in (17)). Up until recently, the vast  
110 majority of our understanding of the SPC apparatus was gleaned from structural examinations  
111 using electron microscopy-based techniques (12). These methods, however, were unable to  
112 provide mechanistic insight into how this organelle is able to capture and pull in endocytosed  
113 material. Our group has previously published both the identification of the first known SPC  
114 targeted proteins (18) as well as a follow-up characterization of the first enzymatic component, a  
115 myosin motor known as MyoF, which contributes to SPC mediated endocytosis (19). In this prior  
116 work, we also overexpressed an enzymatically dead rigor-mutant of MyoF and found that it  
117 completely blocked measurable endocytic activity. Counterintuitively, however, parasites in  
118 which MyoF was directly knocked out (KO) still demonstrated measurable, yet highly  
119 diminished, endocytosis suggesting that functionally redundant myosin motors may be  
120 contributing to this activity and that the rigor-mutant was acting in a dominant-negative fashion.  
121 As a result, we have identified three additional SPC targeted myosin motors and demonstrated  
122 that two of these are positioned at the pre-oral ridge (MyoB and MyoE), while a third myosin  
123 isoform (MyoC) localizes to the cytopharynx.

124  
125 In this study, we have continued our analysis of the cytopharynx targeted MyoF and MyoC by  
126 generating a double deletion mutant in *T. cruzi*. Parasites lacking both MyoF and MyoC were  
127 completely devoid of measurable endocytic activity that was subsequently restored upon  
128 individual gene complementation. To further characterize the molecular complexes regulating  
129 these motors, we performed co-immunoprecipitation (co-IP) of MyoF and identified an SPC  
130 cytopharynx targeted myosin associated protein (MyAP). Unlike most SPC components  
131 identified to date, orthologs of MyAP were identified in a variety of distantly related protozoans  
132 suggesting a potentially conserved or ancestral role in protozoal phagotrophy. Deletion of MyAP  
133 in epimastigotes gave rise to an endocytic-null phenotype that mirrored the double deletion  
134 MyoF and MyoC KO mutants. We utilized both super-resolution and expansion microscopy to  
135 demonstrate that MyAP and the myosin motors are targeted specifically to the SPC microtubule  
136 rootlets and that loss of MyAP resulted in parasites no longer being able to properly target MyoF  
137 and MyoC to these microtubules. While a loss of endocytosis did not directly impact parasite  
138 growth *in vitro*, it led to a dramatic change in the apparent lipid composition of the pre-lysosomal  
139 reservosomes observed in transmission electron-microscopy (TEM) images. High-resolution  
140 mass spectrometry (MS) confirmed this observation and revealed a striking decrease in  
141 scavenged host cholesterol in endocytic-null mutants, whereas the levels of endogenously  
142 synthesized ergosterol (20) remained unchanged. Broadly, this work demonstrates the first use  
143 of gene deletion to produce endocytic-null mutants in *T. cruzi* and lays the groundwork for a full  
144 dissection of the SPC, including the molecular components essential for both the biogenesis  
145 and function of this enigmatic endocytic organelle.

146  
147 **Results:**  
148 **The cytopharynx targeted myosins MyoF and MyoC are necessary for endocytic function.**  
149 In our prior report on the functional characterization of the cytopharynx targeted MyoF in  
150 *Trypanosoma cruzi*, we over-expressed a catalytically dead rigor-mutant of MyoF that had the

151 effect of completely blocking measurable endocytosis (19). In addition to the surprising  
152 revelation that this endocytic-null mutant exhibited no significant changes in growth or viability in  
153 culture, this observation led us to believe that MyoF was an essential component of the  
154 endocytic complex. However, after the generation of a homozygous knockout (KO) of MyoF, we  
155 still observed detectable levels of endocytosis, suggesting that redundant or compensatory  
156 myosin motor activity may be present. With this in mind, we localized the remaining orphan  
157 myosins in *T. cruzi* and observed that isoforms MyoB and MyoE localized to the pre-oral ridge  
158 (POR) region of the cytosome-cytopharynx complex (SPC) while MyoC targeted to the  
159 cytopharynx much like MyoF (**Figure 1** structural schematic and microscopy localization). This  
160 result bolstered our hypothesis that additional myosins were potentially involved in endocytosis  
161 and, as a test, we used CRISPR/Cas9 (**Figure 2A** methodology) to delete MyoC both alone  
162 ( $\Delta MyoC$ ) and in combination with MyoF ( $\Delta F\Delta C$ ) (**Figure 2B** and **2C** polymerase chain reaction  
163 (PCR) validation for MyoC and MyoF loci changes). We also complemented MyoC back into the  
164 double  $\Delta F\Delta C$  background ( $\Delta F\Delta C::C-Ty$ ) and validated its proper localization to the cytopharynx  
165 using immunofluorescence microscopy (IFA) (**Figure 2D**). While the loss of MyoC alone had a  
166 negligible effect on the overall rate of endocytosis as compared to  $\Delta MyoF$  (**Figure 2E** and  
167 quantified in **2G** (green  $\Delta MyoC$  and blue  $\Delta MyoF$ )), deletion of both MyoF and MyoC ( $\Delta F\Delta C$ )  
168 resulted in a severe defect in endocytic rate on a par with our chemical inhibitor of endocytosis:  
169 the actin polymerization inhibitor cytochalasin D (+CytD) (**Figure 2F** and quantified in **2G** (gray:  
170 +CytD and red:  $\Delta F\Delta C$ )). As expected, complementation of MyoC restored the endocytic rate to  
171 the original  $\Delta MyoF$  levels (**Figure 2F** and quantified in **2G** (yellow)). As observed previously  
172 when we overexpressed the rigor-mutant of MyoF, loss of these motors and endocytic function  
173 as a whole, had no significant effect on parasite growth *in vitro* (**Supplementary Figure S1A**  
174 and **S1B**). Endocytosis, therefore, appears to rely primarily on MyoF, with MyoC also  
175 contributing significantly to this activity as evidenced by the double deletion mutant.  
176

177 **A MyoF associated protein localizes to the microtubule rootlets of the SPC.** To begin  
178 identifying the protein components associated with the MyoF motor complex, we carried out co-  
179 immunoprecipitation (co-IP) and mass spectrometry (MS) analysis of *T. cruzi* parasites  
180 overexpressing MyoF fused to the fluorescent protein mNeon and the Ty-tag epitope (**Figure**  
181 **3A** top: protein gel and bottom: MS results). From this work, we identified a myosin associated  
182 protein (MyAP) which contains a putative calcium responsive paired EF-hand (EFh) domain (21)  
183 and a highly ubiquitous protein interaction module known as a leucine-rich repeat (LRR) (22)  
184 (**Figure 3B** top: MyAP AlphaFold prediction, EFh in blue and LRR in green and bottom: linear  
185 protein schematic). The presence of the EFh pair suggested a potential role in regulating motor  
186 function as these calmodulin-like domains are known to bind IQ motifs which are also predicted  
187 to be present in MyoF (23). In examining the genome of Y-strain *T. cruzi* (DTU II) (24, 25), we  
188 discovered the presence of two paralogs of MyAP (**a**: TcYC6\_0120270 and **b**: TcYC6\_0120590)  
189 which are distinguished solely by the insertion of six amino acids (QYSSTQ) in the N-terminal  
190 portion of the subtype **b** protein (**Figure 3B** bottom: vertical red line denotes insertion location).  
191 We localized the overexpressed fusion of MyAP-mNeon-Ty (subtype **b**) in transfected parasites  
192 and observed its targeting to the now-familiar SPC-like linear structure (**Figure 3C** green). To  
193 confirm co-localization of MyAP and components of the SPC, we first generated a mouse  
194 polyclonal antibody to a predicted antigenic region of MyAP (**Figure 3B** bottom; horizontal pink  
195 line denotes antigen). Using the resulting antibody, we conducted an IFA on parasites  
196 expressing the MyoF-mNeon-Ty fusion protein and observed clear overlap of the MyAP (red)  
197 and MyoF (green) fluorescent signals (**Figure 3D**). In order to localize MyAP with greater  
198 precision within the SPC itself, we conducted expansion microscopy on *T. cruzi* epimastigotes  
199 combined with an IFA against the Ty-epitope using our MyAP-Ty complemented line. Utilizing  
200 the TAT-1 anti- $\alpha$ -tubulin antibody (26, 27) to highlight parasite microtubules, we were able to  
201 demonstrate that MyAP-Ty specifically targets to the microtubule rootlets rather than the

202 membrane tubule of the SPC (**Figure 3E** left panel). In addition, we examined the localization of  
203 both MyoF-Ty and MyoC-Ty using this same methodology and found that these motors also  
204 associated with the SPC microtubules (**Figure 3E** middle and right panels respectively) thus  
205 validating previous observations of MyoF using immuno-electron microscopy (28). Additional  
206 representative images demonstrating MyAP, MyoF and MyoC localizations are also presented  
207 in **Supplementary Figures S2A, S2B** and **S2C** respectively. As a negative control, the  
208 untagged parental and  $\Delta MyAP$  strains failed to show any appreciable fluorescent signal on the  
209 cytosomal microtubules (**Supplementary Figures S2D** and **S2E** respectively). To further  
210 demonstrate MyAP's association with the parasite microtubular cytoskeleton, we fractionated *T.*  
211 *cruzi* epimastigotes into detergent soluble and insoluble cytoskeletal fractions and, using  
212 Western blot analysis, observed an enrichment of MyAP with the cytoskeletal fraction with the  
213 protease Cruzipain serving as a marker for the detergent soluble fraction (**Supplementary**  
214 **Figure S3**) (29).

215  
216 To date, the vast majority of proteins we have identified as being targeted to the endocytic  
217 structure can be found only in SPC containing kinetoplastids. A broad phylogenetic analysis of  
218 the MyAP protein, however, has shown that orthologs of this protein can be found in a variety of  
219 protozoans including *Leishmania spp.* (**Figure 3F** phylogenetic tree and **Supplementary Figure**  
220 **S4** sequence alignment). Although *Leishmania spp.* lack an SPC and endocytose exclusively  
221 via the flagellar pocket, they nonetheless appear to retain a vestigial microtubule rootlet-like  
222 tract (similar to the CyQ/CyT) along which endocytosed material is trafficked to the cell posterior  
223 (30, 31) and it remains possible that the leishmanial MyAP ortholog may localize to this  
224 microtubule track as well. More broadly, however, the presence of MyAP orthologs in distantly  
225 related SPC containing species, including ciliates, highlights the potential for an evolutionarily  
226 conserved role in protozoan endocytosis.

227  
228 **Loss of MyAP results in ablation of endocytosis and mistargeting of both MyoF and**  
229 **MyoC.** To assess the functional role of MyAP in endocytosis, we implemented the  
230 CRISPR/Cas9 dependent gene deletion strategy, as performed previously with MyoF and  
231 MyoC. We deleted both paralogs of MyAP simultaneously using the same CRISPR targeting  
232 gRNA and drug selection cassette (**Figure 4A** methodology). We first generated a clonal cell  
233 line lacking both chromosomal copies of paralogs *a* and *b* of MyAP ( $\Delta MyAP$ ) and used this  
234 clone to, in turn, generate a complemented line with the subtype *b* paralog ( $\Delta MyAP::MyAP-Ty$ ).  
235 We verified disruption and restoration of the MyAP locus using diagnostic PCR (**Figure 4B**) and  
236 showed the loss and restoration of protein expression using our in-house derived MyAP  
237 antibody (**Figure 4C** Western blot). Following deletion of MyAP, we subjected parasites to our  
238 flow cytometry-based feeding assay and found that the deletion mutants demonstrated a  
239 complete lack of measurable endocytic activity while the complementation of MyAP-Ty fully  
240 restored endocytosis (**Figure 4D** and quantified in **4E**). The loss of MyAP and associated  
241 endocytic function also did not alter the growth of epimastigotes *in vitro* (**Supplementary Figure**  
242 **S1C** and **S1D**). In observing the essentiality of MyAP for endocytic function, we were curious if  
243 this impacted MyoF or MyoC overtly. We transfected the parental, null mutant ( $\Delta MyAP$ ) and  
244 complemented lines ( $\Delta MyAP::MyAP-Ty$ ) (**Figure 4F** left, middle and right panels respectively),  
245 with either the MyoF or MyoC-mNeon-Ty fusion constructs and examined myosin motor  
246 localization after 24 hours (hrs). Intriguingly, mutants lacking MyAP demonstrated an inability to  
247 properly target MyoF and MyoC to the canonical linear cytopharynx structure of the SPC and  
248 were instead found to be distributed diffusely throughout the cytosol (**Figure 4F** middle panels).  
249 MyAP complemented parasites restored normal localization of both motors (**Figure 4F** right  
250 panels). It is also worth noting that MyoB and MyoE were unaffected by the loss of MyAP and  
251 continued to be properly targeted to the pre-oral ridge region (**Supplementary Figure S5A**).  
252 Additionally, loss of MyoF or MyoC either separately or together did not impact the localization

253 of MyAP suggesting that MyAP's localization does not rely on the presence of myosin motors  
254 (**Supplementary Figure S6**). Using expansion microscopy, we were also able to show that loss  
255 of MyAP did not directly affect the cytosomal microtubules (CyQ: red arrow, and CyT: green  
256 arrow) (**Supplementary Figure S2F**). This data, therefore, suggests that MyAP plays a critical  
257 role in the specific recruitment of MyoF and MyoC to the SPC rootlet microtubules, thus  
258 potentially explaining why the severity of the observed endocytic defect mirrors the  $\Delta F\Delta C$   
259 knockout line.

260

261 **The paired EF-hand structure is essential for MyAP function independent of its myosin**  
262 **motor recruitment activity.** How the cytopharynx myosins (MyoF and MyoC) are targeted to  
263 the SPC and regulated remained an unknown aspect of this endocytic organelle's function. With  
264 the discovery that MyAP is necessary for the proper localization of these motors, we aimed to  
265 dissect the functional contribution of the major identified LLR and EFh domains of MyAP to this  
266 activity (**Figure 5A** schematic). Using the endocytic null  $\Delta MyAP$  line as the background strain,  
267 we first generated individual domain deletion constructs of MyAP lacking either the LRR or EFh  
268 domains and reintroduced this mutant gene into the endogenous locus in a manner analogous  
269 to that used in the original complementation line (see **Figure 4A** methodology). Clonal cell lines  
270 of both the  $\Delta MyAP::MyAP\Delta LRR-Ty$  (green arrow) and  $\Delta MyAP::MyAP\Delta EFh-Ty$  (blue arrow)  
271 complements were isolated and validated via diagnostic PCR (**Figure 5B**) and Western blot  
272 analysis of mutant MyAP protein expression (**Figure 5C**). We initially characterized the capacity  
273 of these complementation mutants to restore endocytic function and found that the loss of the  
274 LRR domain was not detrimental and endocytosis was restored to parental line levels (**Figure**  
275 **5D** and quantified in **5E** (green)). In contrast, the EFh proved critical, as loss of this domain  
276 mirrored the phenotype of the parent  $\Delta MyAP$  KO line (**Figure 5D** and quantified in **5E** (blue)). At  
277 this point, it was unclear how these deletion mutants were impacting myosin motor localization,  
278 so we again examined the targeting of MyoF-mNeon in both the LRR ( $\Delta MyAP::MyAP\Delta LRR-Ty$ )  
279 and EFh deletion ( $\Delta MyAP::MyAP\Delta EFh-Ty$ ) lines. We found that neither a lack of an LRR nor  
280 EF-hand impacted proper targeting of MyoF-mNeon to the cytopharynx (**Figure 5F**). The EF-  
281 hand, therefore, appears dispensable for myosin recruitment, yet may still function to regulate  
282 the activity of the motor protein itself as is often the case with regulatory myosin light chain  
283 proteins (32). We next examined the functional contribution of three predicted calcium  
284 coordinating aspartic acid residues of the EF-hand through mutational analysis (D616A, D641A  
285 and D652A) (**Supplementary Figure S7A** EFh AlphaFold structure with aspartic acid residues  
286 highlighted). The resulting complementation mutants were validated via diagnostic PCR and  
287 Western blotting (**Supplementary Figure S7B** and **S7C**). Endocytic activity of the resulting  
288 complemented mutant lines was found to be indistinguishable from wild-type MyAP  
289 (**Supplementary Figure S7D**) (33-35). While the EFh domain in its entirety is essential for  
290 endocytic activity, our attempts to compromise this structure's ability to bind calcium failed to  
291 disrupt endocytosis. This result suggests that either the EFh domain no longer binds calcium or  
292 alternatively that when calcium is bound it serves to negatively regulate motor function.

293

294 **Loss of endocytosis reduces lipid uptake and storage in epimastigote reservosomes.**

295 Although the ablation of MyAP had a severe impact on endocytosis in *T. cruzi* epimastigotes, it  
296 was unclear as to how this was impacting the SPC or internal organellar structures, as no clear  
297 impact on growth *in vitro* had been observed (**Supplementary Figure S1C** and **S1D**). We  
298 subjected parental Y-strain and  $\Delta MyAP$  KO parasites first to scanning electron microscopy  
299 (SEM) in order to assess changes to the cytosome opening. We found that the loss of MyAP  
300 had no overt effect on the overall size and appearance of the cytosome at the surface of these  
301 parasites (**Figure 6A**). We next examined the internal structures of the parasite and employed  
302 transmission electron microscopy (TEM) to compare parental,  $\Delta MyAP$  KO and  $\Delta MyAP::MyAP-$   
303 *Ty* complemented epimastigotes and observed that endocytic-null mutants demonstrated a

304 marked difference in the composition of their pre-lysosomal reservosome storage structures  
305 (**Figure 6B** middle: orange panel green outlined vesicles). Although still present, the  
306 reservosomes of the  $\Delta MyAP$  mutant lacked the typical electron lucent voids indicative of lipid  
307 inclusions and thus appeared uniformly electron dense (36). This suggested that parasites were  
308 no longer able to accumulate lipids in their reservosomes via endocytosis. Complementation of  
309 MyAP in the deletion strain ( $\Delta MyAP::MyAP-Ty$ ) restored both endocytic capacity and the  
310 presence of the lipid inclusions (**Figure 6B** right: red outlined panel and green outlined  
311 vesicles). To obtain a direct look at the parasite lipidome, we analyzed the compositional  
312 changes in sterol makeup of endocytic null mutants. We subjected Parental,  $\Delta MyAP$  and  
313  $\Delta MyAP::MyAP-Ty$  complemented epimastigote parasites, grown to log phase *in vitro*, to MS  
314 based lipidomics analysis. The sterol composition of fresh epimastigote LIT/LDNT media was  
315 also assessed in parallel (37). A principal component analysis of the dataset demonstrated the  
316 significant differences in the  $\Delta MyAP$  lipid profiles as compared to the parental and  
317  $\Delta MyAP::MyAP-Ty$  complemented lines (**Supplementary Figure S8A**). We first compared the  
318 main, endogenously synthesized, parasite specific sterol (ergosterol) to the exclusively  
319 scavenged host-derived, or in this case media derived, sterol (cholesterol) (20, 38). In this  
320 analysis we found that while endogenously synthesized ergosterol levels were unchanged in all  
321 three parasite strains regardless of endocytic capacity, scavenged cholesterol was dramatically  
322 reduced only in the endocytic-null mutant, with levels being restored in the complemented line  
323 (**Figure 6C**). This analysis further supports the myriad observations we have presented here,  
324 demonstrating that these endocytic-null mutant parasites lack the ability to actively phagocytose  
325 via their SPC and thus fail to accumulate exogenous nutrients into their reservosomes.

326

### 327 **Discussion:**

328 In our previously published study, we identified four distinct orphan myosin motors that are  
329 targeted to the oral apparatus of *Trypanosoma cruzi* and characterized the contribution of the  
330 cytopharynx targeted MyoF to SPC mediated endocytosis (19). Here we have continued this  
331 dissection of the molecular machinery responsible for *T. cruzi* endocytosis by focusing on the  
332 two cytopharynx localized myosins: MyoF and MyoC. While the deletion of MyoF alone  
333 significantly reduced the rate of endocytosis, the combined deletion of both motors ( $\Delta F\Delta C$ )  
334 produced endocytic-null parasites that lacked detectable levels of protein uptake. The ablation  
335 of endocytosis, again, had no significant effect on the growth rate of *T. cruzi*, further supporting  
336 the notion that this process is not essential for viability under laboratory culture conditions (19).

337

338 To begin expanding our understanding of the protein complexes contributing to SPC function,  
339 we carried out a co-IP of overexpressed MyoF-mNeon-Ty in insect stage epimastigotes followed  
340 by mass spectrometry analysis. From this, we identified a protein containing both an N-terminal  
341 leucine rich repeat (LRR) and a putative C-terminal calcium responsive paired EF-hand (EFh)  
342 structure which we refer to as the myosin associated protein or MyAP. This protein was chosen  
343 for further study due in part to the presence of the paired EF-hand domain which we suspected  
344 might interact with the IQ motifs found on MyoF to possibly regulate motor function (39, 40).  
345 Upon closer examination of the Y-strain genome (24), we also discovered that MyAP existed as  
346 two distinct paralogs (which we refer to as subtype **a** and **b**) distinguished solely by the  
347 presence of a six amino acid insertion. We first confirmed MyAP's SPC localization using IFAs  
348 by either overexpressing it as an mNeon fusion protein or staining the endogenous protein with  
349 our in-house generated MyAP antibody. Both techniques demonstrated a clear localization of  
350 MyAP to the SPC cytopharynx structure. However, because the cytopharynx complex itself is  
351 composed of both a dynamic membrane tubule as well as adjacent stable microtubule rootlets,  
352 we set out to determine with greater precision the location of MyAP within this region of the  
353 endocytic apparatus itself. With the aid of expansion-based immunofluorescence microscopy,  
354 we were able to show that MyAP is fixed upon the microtubule rootlet structure, rather than on

355 the more dynamic membrane tubule. This technique also allowed us to examine the localization  
356 of MyoF and MyoC and we found both motors also localized on these root fibers beginning at  
357 the cytostome entrance. The targeting of MyoF to these microtubules validates prior  
358 observations by Alves et al. who, by using immuno-EM of epitope tagged MyoF on membrane  
359 extracted *T. cruzi* cytoskeletons, demonstrated that MyoF associates with SPC rootlet  
360 microtubules ((28) and reviewed in (12)). Our subsequent direct deletion of both MyAP paralogs  
361 using CRISPR/Cas9, resulted in endocytic-null parasites that phenocopied our myosin double  
362 deletion mutants ( $\Delta F\Delta C$ ) and we were able to completely restore this endocytic defect via  
363 complementation. The essentiality of MyAP to endocytosis and its presence in a number of  
364 distantly related SPC containing protozoans leads us to believe that this protein may play an  
365 ancestrally conserved role in SPC mediated protozoal phagotrophy. To address the means by  
366 which MyAP was impacting endocytosis, we first localized MyoF and MyoC in the  $\Delta MyAP$  line  
367 and, intriguingly, we found that the cytopharynx motors were cytosolic and no longer associated  
368 with the SPC. Proper targeting of MyoF/C was again restored when MyAP was complemented  
369 back into the KO. It, therefore, appeared likely that the reason the loss of MyAP phenocopies  
370 the  $\Delta F\Delta C$  endocytic defect is due, in part, to the inability to recruit MyoF/C to the cytostomal  
371 microtubules, a seemingly necessary step in facilitating endocytosis. What this work has not yet  
372 demonstrated, however, is if this interaction between MyAP and the motors is direct or if there  
373 are additional protein factors involved which mediate these interactions. With respect to the  
374 overall model of SPC function, these observations suggest that the movement of endocytosed  
375 membrane into the cell cytosol is propelled by a linear array of myosin motors fixed onto rootlet  
376 microtubule structures. We reason that since these motors must walk on actin filaments, likely in  
377 a plus-end directed fashion, the actin polymers themselves must be associating with the  
378 cytopharynx membrane in a polarized orientation. This model, therefore, predicts that the  
379 polymerization of actin is likely initiated at the cytostome entrance in order to coat the emerging  
380 cytopharynx membrane with polarized microfilaments that the fixed myosins can pull on  
381 unidirectionally (reviewed in (12)).

382  
383 In examining the functional role of the two identified domains found in MyAP (LRR and EFh) we  
384 reintroduced, via complementation, the MyAP gene lacking either the LRR domain or the EFh.  
385 While the LRR domain appeared fully dispensable for normal protein function, loss of the EFh  
386 failed to restore endocytosis. We initially hypothesized that the EFh was playing a role in myosin  
387 motor recruitment but, to our surprise, we found that the *MyAP $\Delta$ EFh-Ty* mutant restored proper  
388 MyoF targeting. This implied to us that the MyAP protein is potentially performing two  
389 independent yet necessary functions: recruitment of myosin motors to the SPC microtubules on  
390 the one hand and regulation of myosin motor activity via the EFh on the other. To examine this  
391 possibility in more detail, we next mutated three predicted calcium coordinating aspartic acid  
392 residues of the EFh and found that none of these mutations negatively impacted endocytosis.  
393 Although we have yet to directly confirm the calcium binding capability of this EFh  
394 biochemically, our mutations of conserved residues indicate that the structural fold of the  
395 calcium-free EF-hand is sufficient to activate motor activity. This data also implies that if calcium  
396 binds to this domain, it likely promotes EFh disengagement leading to shutdown of the motor in  
397 a manner analogous to other EF-hand containing calmodulin myosin light chains (41-43). If this  
398 is the case, our results simply mirror prior studies where calcium binding mutants of calmodulin  
399 are unable to dissociate and lead to myosin motors which are constitutively active. A more  
400 complete understanding of the role that the MyAP EFh has on regulating MyoF/C motor activity  
401 will, in all likelihood, require biochemical analyses of purified proteins to characterize the nature  
402 of binding and activation of myosin activity by MyAP. More broadly, this observation raises the  
403 interesting prospect that calcium signaling itself may play an important role in regulating *T. cruzi*  
404 endocytosis.

405



406 In the absence of a clear *in vitro* growth defect exhibited by our endocytic null mutants, we  
407 continue to be faced with the central question regarding the ultimate role of endocytosis in this  
408 parasite's life cycle. Although we have speculated extensively in our prior reports as to why the  
409 SPC was retained specifically in those trypanosomatids that are transmitted via the insect feces,  
410 we still lack definitive evidence showing when or where endocytosis is essential in the parasite  
411 life cycle (12, 19). However, what we have been able to demonstrate here using TEM and MS-  
412 based lipidomics analyses, is that these mutants have a dramatically reduced capacity to take in  
413 and store extracellular material such as host-derived cholesterol in their reservosome  
414 structures. Prior reports have shown that reservosomes play an important role in nutrient  
415 provisioning under starvation conditions since they transition from storage depots into digestive  
416 lysosomes to fuel the metabolic needs of metacyclogenesis, a necessary step in transmission  
417 (44-46). It remains possible that, when lacking endocytosis, parasites will present markedly  
418 reduced fitness under specific nutrient stress conditions. Future detailed parasite-vector studies  
419 will be needed to examine the ability of these endocytic-null parasites to effectively colonize the  
420 insect intestine, compete for nutrients and space with the associated insect microbiome and  
421 ultimately undergo metacyclogenesis as they prepare to infect their eventual vertebrate host.  
422 These studies will be the necessary next step if we are to provide a definitive answer as to why  
423 *T. cruzi* retained this ancestral feeding structure.  
424

425 In conclusion, it is worth restating that the endocytic organelle which we have discussed and  
426 referred to here as the cyto~~s~~to~~m~~e-cytopharynx complex or SPC, is a fascinatingly complex and  
427 ubiquitous feeding structure found in vast numbers of heterotrophic protozoans which populate  
428 the world's various ecosystems. In spite of both its presence in myriad protozoan species that  
429 play critical roles in environmental nutrient cycling and human disease, we know next to nothing  
430 about how the SPC is formed or functions at a mechanistic level. Using the human kinetoplastid  
431 parasite *Trypanosoma cruzi* as a model, our group has been able to initiate a systematic  
432 dissection of the structural and mechanistic underpinnings of the SPC organelle. By taking  
433 advantage of the fact that *T. cruzi* is both genetically tractable and does not require SPC  
434 function for *in vitro* growth we can examine the molecular components of this organelle without  
435 negatively impacting parasite fitness in culture. This, in the end, is a fortuitous finding since *T.*  
436 *cruzi* continues to lack the necessary genetic tools to study the function of essential genes (47).  
437 An array of important questions regarding the formation and regulation of the SPC organelle  
438 clearly still remain and future studies will no doubt continue to provide important insight into the  
439 molecular mechanisms undergirding this fundamental process of protozoan phagotrophy.  
440

441 **Acknowledgments:** We would like to sincerely thank the members of the Center for Tropical  
442 and Emerging Global Diseases (CTEGD), Julie Nelson and the CTEDG Cytometry Shared  
443 Resource Laboratory, the T32 Training in Tropical and Emerging Global Diseases grant  
444 (T32AI060546) and funding from the NIH (R01AI163140 and R01GM144545).  
445

## 446 **Materials and Methods:**

### 447 **Parasite cultures.**

448 Y-strain epimastigotes were cultured in LIT/LDNT medium (37) supplemented with 15% 76°C  
449 heat-inactivated fetal bovine serum (FBS) (VWR, USDA certified). To obtain amastigotes,  
450 metacyclic trypomastigotes generated via epimastigote starvation as previously described (18)  
451 were added to T25 flasks or coverslips containing confluent human foreskin fibroblasts (HFF).  
452 Infected monolayers were maintained in high-glucose Dulbecco's modified Eagle's medium  
453 (DMEM-HG) (HyClone) supplemented with L-glutamine and 1% 56°C heat-inactivated Cosmic  
454 Calf serum (CCS) (HyClone).  
455  
456

457 **Epimastigote growth assays.**

458 Standard growth assays were performed as previously described (18).  $5.0 \times 10^6$ /ml  
459 epimastigotes of each line were seeded into 2 mL LIT media containing 15% of 76°C  
460 heat-inactivated FBS in a T12.5 flask. Counting every 24 hrs was performed using a Z1 Coulter  
461 counter (Beckman Coulter) counting at a 1:200 dilution and averaging three counts per sample.  
462 Cumulative growth assays were performed as described above except that the parasite  
463 concentration was reset to  $5.0 \times 10^6$ /ml each day with fresh media after counting.

464

465 **Transfections and overexpression.**

466 Transfections were performed as previously described (48) with some modifications.  
467 Precipitated DNA pellets were initially resuspended in 10  $\mu$ L nutrient free TAU containing 5%  
468 76°C heat inactivated FBS, prior to adding cells with in electroporation buffer.  $2.5 \times 10^7$   
469 epimastigotes were transfected using two pulses of the BTX ECM 830 system (Harvard  
470 Apparatus) for all transfections. A list of primers used during this work can be found in Table S1  
471 in the supplemental material. For overexpression of MyoC-mNeonTy and MyoF-mNeonTy in  
472 MyAP knockout epimastigotes, the plasmids generated in our previous work (19) were used.

473

474 **Co-immunoprecipitation and liquid chromatography/mass spectroscopy.**

475 Co-immunoprecipitation of overexpressed MyoF-mNeonTy using an anti-Ty antibody was  
476 performed as previously described (18, 49). Eluates were run briefly on an Any-kD SDS-PAGE  
477 gel (BioRad) to separate out most of the Ty peptide used for the elution process and then the  
478 lane was excised prior to washing in 50% methanol for LC/MS analysis. The samples were  
479 analyzed via data-dependent electrospray LC-MS/MS on a Thermo Q-Exactive Orbitrap mass  
480 spectrometer. Trypsin was selected as the protease, with maximum missing cleavage set to 2.  
481 A 1% false discovery rate cutoff was selected for peptide, protein, and site identifications. MS  
482 results were searched against the Y-strain YC6 genome (tritrypdb.org).

483

484 **Gene deletion and complementation using CRISPR/Cas9.**

485 Deletion and complementation were performed as previously described (19, 48) with  
486 modifications. G418 (1,000  $\mu$ g/ml) added 24 hrs after Cas9 transfections was only maintained  
487 for 3 days when using Blasticidin repair templates for gene deletions and 5 days when using  
488 Hygromycin repair templates for complementation, to help stall the growth of untransfected  
489 epimastigotes immediately after transfection. Other aspects of this methodology including  
490 plasmids used (pTMiniTrex), gRNA design, and subcloning were consistent with the previously  
491 published method cited above. Double gene deletion was performed sequentially using a  
492 Blasticidin resistance repair template for MyoF and a Hygromycin resistance repair template for  
493 MyoC. Complementation of double knockouts utilized the G418 resistance cassette and  
494 selection with only 250  $\mu$ g/mL G418 after the initial 72 hrs (during which the normal 1000  $\mu$ g/mL  
495 was used). Mutagenesis of complement templates was performed using the Q5 Mutagenesis kit  
496 (NEB) with primers referenced in the primer table S1.

497

498 **Western blotting and fluorescent microscopy.**

499 Western blotting was performed as previously described(18). Mouse anti-MyAP antibody was  
500 used at 1:500. Fluorescence microscopy was performed as previously described with  
501 modifications for the MyAP antibody images (18). A modified fixation protocol was used for the  
502 MyAP antibody images to improve MyAP labeling.  $1 \times 10^7$  epimastigotes were pelleted at 1,000 x  
503 g for in a 1.5 mL tube for 3 min. LIT/LDNT culture media supernatant was removed and then,  
504 without disturbing the pellet, the epimastigotes were fixed with a rapid addition of 1 mL of -20°C  
505 Methanol and disruption of the pellet. Fixation was continued at -20°C for 5 min then transferred  
506 to -80°C for an additional 10 min to maintain cold temperature during the proceeding spin. Fixed  
507 parasites were spun down in a 4°C centrifuge at 1,500 x g for 3 min, then washed three times in

508 1 mL pH 7.4 PBS using the same 1,500 x g spins. ConA labeling and the remaining IFA steps  
509 were performed as previously described (18). Mouse polyclonal anti-MyAP was used in IFAs at  
510 a 1:200 dilution. Rabbit anti-cruzipain antibody (used at 1:1000) was a generous gift from  
511 Roberto Docampo.

512

### 513 **Flow cytometry-based endocytosis assays.**

514 Endocytosis assays were performed as previously described (19).  $5 \times 10^6$  log phase  
515 epimastigotes of each line were pelleted in 1.7 mL centrifuge tubes, washed in 500  $\mu$ L HBSS  
516 (Hanks balanced salt solution) and either treated with 10  $\mu$ M Cytochalasin D or mock treated for  
517 10 min. Epimastigotes were then incubated with Alexa Fluor 647-conjugated BSA for 30 min at  
518 28°C, washed in 10 mL HBSS then resuspended in 1 mL HBSS before being run on a  
519 Quanteon flow cytometer (Acea Bio). Analysis was performed using FlowJo software.

520

### 521 **Sequence alignment, tree generation and structure prediction.**

522 Alignments were performed using the T-Coffee alignment server (50) and alignment figures  
523 were generated using Jalview 2 software (51). Consensus tree of predicted MyAP orthologues  
524 (identified via NCBI Blast (52)) was generated in the Geneious Prime software suite using the  
525 Jukes-Cantor Genetic Distance Model, Neighbor-Joining tree build method, and Bootstrapped.  
526 Structure prediction of MyAP was obtained from the AlphaFold database  
527 (<https://alphafold.ebi.ac.uk/entry/Q4E2K6>) (53) and figures generated using Pymol software  
528 (Schrodinger).

529

### 530 **Transmission electron microscopy.**

531 For morphological analyses at the ultrastructural level, parasites were fixed in 2%  
532 paraformaldehyde/2.5% glutaraldehyde (Ted Pella Inc., Redding, CA or other source) in 100  
533 mM sodium cacodylate buffer, pH 7.2 for 2 hr at room temperature. Samples were washed in  
534 sodium cacodylate buffer at room temperature and post-fixed in 2% osmium tetroxide (Ted Pella  
535 Inc) for 1 hr at room temperature. Samples were then rinsed in dH<sub>2</sub>O, dehydrated in a graded  
536 series of ethanol, and embedded in Eponate 12 resin (Ted Pella Inc). Sections of 95 nm were  
537 cut with a Leica Ultracut UCT ultramicrotome (Leica Microsystems Inc., Bannockburn, IL),  
538 stained with uranyl acetate and lead citrate, and viewed on a JEOL 1200 EX transmission  
539 electron microscope (JEOL USA Inc., Peabody, MA) equipped with an AMT 8 megapixel digital  
540 camera and AMT Image Capture Engine V602 software (Advanced Microscopy Techniques,  
541 Woburn, MA).

542

### 543 **Scanning electron microscopy.**

544 Epimastigotes were fixed in a freshly prepared solution of LIT/LDNT media with 2%  
545 paraformaldehyde/2.5% glutaraldehyde for 1 hr at room temperature. Post-fixation, SEM  
546 samples were gently pelleted and washed in 0.15 M cacodylate buffer. This was repeated two  
547 additional times after which the samples were incubated with 1% osmium tetroxide in 0.15 M  
548 cacodylate buffer for 45 min in the dark. The samples were then gently pelleted and washed in  
549 ultrapure water. After three rinses, pelleted samples were resuspended in 100  $\mu$ l of ultrapure  
550 water and loaded onto coverslips freshly coated with 1 mg/ml poly-L-lysine. Cells were allowed  
551 to settle and attach to the coverslips for an hour. Samples were then dehydrated in a graded  
552 ethanol series (10%, 30%, 50%, 70%, 90%, 100% x 3) for 10 min each step. Following  
553 dehydration, the samples were loaded into a critical point drier (Leica EM CPD 300, Vienna,  
554 Austria) which was set to perform 12 x CO<sub>2</sub> exchanges at the slowest speed. Once dried,  
555 coverslips were mounted on aluminum stubs with carbon adhesive tabs and coated with 10 nm  
556 of carbon and 10 nm of iridium (Leica ACE 600, Vienna, Austria). SEM images were acquired  
557 on a FE-SEM (Zeiss Merlin, Oberkochen, Germany) at 1.5 kV and 0.1 nA.

558

559 **Ultrastructure expansion microscopy.**

560 For each expansion gel, a volume of 2x fixative was added to  $1 \times 10^6$  cells in an equal volume of  
561 media to provide a 1x final concentration of fixatives: 0.7% paraformaldehyde (Thermo Fisher  
562 Scientific), 1% acrylamide (Bio-Rad, Hercules, CA), in 1x PBS (Fisher Scientific, Pittsburgh PA).  
563 Cells were harvested by centrifugation at 1000 x g for 10 min, then washed with 1x fixative  
564 (0.7% paraformaldehyde, 1% acrylamide, 1x PBS) and the centrifugation step repeated. Cell  
565 pellets were resuspended in 1x fixative and were briefly spun onto coverslips at  $800 \times g$  for 5  
566 sec. The slow speed and short time preserve the morphology of the cells. The coverslips were  
567 inverted onto 80  $\mu$ L droplets of 1x fixative in a humidified chamber for 3.5 hr at 37°C. Coverslips  
568 were then inverted into gelation solution (19% sodium acrylate (Pfaltz & Bauer, Waterbury CT),  
569 10% acrylamide, 0.1 % Bis (Bio-Rad), in 1x PBS) activated with 0.5% TEMED (Bio-Rad) and  
570 0.5% ammonium persulfate (Sigma-Aldrich, St. Louis, MO). Gelation reaction was allowed to  
571 solidify for 1 hr at 37°C. Gels on coverslips were incubated in denaturation buffer (200 mM  
572 sodium dodecyl sulfate (Fisher Scientific), 200 mM sodium chloride (Fisher Scientific), 50 mM  
573 TRIS Base (Fisher Scientific)) for 15 min at RT. Gels were then carefully peeled away from  
574 coverslip into a 1.6 mL microcentrifuge tube and then incubated in denaturation buffer at 95°C  
575 for 30 min. Gels were incubated in large petri dishes filled with deionized water to expand. A  
576 water change was done after 30 min and the gels were then allowed to expand fully overnight.  
577 The following day, the gels were shrunk in 1x PBS for 30 min. Shrunken gels were incubated in  
578 primary antibodies in 2% BSA (Fisher Scientific) in 1x PBS for 4 hr. Gels were washed 3 times  
579 in 1x PBS with 0.1% Tween-20, for 20 min each wash. Gels were then incubated in secondary  
580 antibodies in PBS with 2% BSA for 4 hr followed by three 20 min washes in 1x PBS with 0.1%  
581 Tween-20. Gels were transferred to large petri dishes filled with deionized water for expansion.  
582 After 30 min, the water was exchanged with fresh deionized water and the gels were allowed to  
583 fully expand overnight. The next day, gel punches were imaged on glass bottom microwell  
584 dishes (MatTek Corporation, Ashland, MA). Expansion microscopy images were taken on a  
585 Zeiss Axio Observer.Z1 microscope (Carl Zeiss Microscopy, Oberkochen, Germany) using a  
586 100x/1.4 NA Plan Apochromat oil objective lens imaged with an ORCA-Flash 4.0 V2 CMOS  
587 camera (Hamamatsu—Shizuoka, Japan). Images were acquired in Slidebook 6 software (3i,  
588 Denver, CO) as z-stacks with a step size of 250 nm. Microscopy images were visualized with  
589 ImageJ (National Institutes of Health, Bethesda, MD), and figures prepared in Adobe Photoshop  
590 and Illustrator (CC 2022). Antibodies for expansion microscopy were sourced and diluted as  
591 follows: anti-Ty1 antibody (1:10) from Cynthia He (National University of Singapore, Singapore),  
592 anti-TAT1 antibody (1:100) from Jack Sunter (Oxford Brookes University—Oxford, United  
593 Kingdom). Secondary antibodies Goat anti-mouse IgG1 Alexa Fluor 488 (Thermo Fisher  
594 Scientific, Waltham MA) and goat anti-mouse IgG2a Alexa Fluor 568 (Thermo Fisher Scientific)  
595 were used at 1:100 dilution.

596

597 **Detergent fractionation for evaluation of cytoskeleton association.**

598 Detergent fractionation was performed similar to described by Alves et al. (28) with  
599 modifications.  $30 \times 10^6$  epimastigotes were washed 1x with cold Brinkley Buffer 1980 (BRB80,  
600 80mM PIPES pH 6.8, 1 mM  $MgCl_2$ , 1 mM EGTA, 1 mM EDTA) + 0.1 mM EDTA and Complete  
601 Protease Inhibitors (Roche). Detergent treatment was performed by adding 1% NP40 in BRB80  
602 for 10 min at 4°C. After Centrifugation at maximum speed, the supernatant was spun down a  
603 second time and removed to a separate tube as the detergent soluble fraction. The detergent  
604 insoluble pellet was washed twice with 1 mL of BRB80 buffer +1% NP40 before being  
605 resuspended and boiled in SDS PAGE Buffer for SDS PAGE and immunoblot as described  
606 above.

607

608 **Statistical analysis.**

609 Statistical analysis was performed using the Prism Software suite unpaired *t*-test function. Three  
610 biological replicates were performed for each analyzed experiment. *P* values are denoted as  
611 follows: \*, *P* < 0.05; \*\*, *P* < 0.01; \*\*\*, *P* < 0.001; \*\*\*\*, *P* < 0.0001.

612  
613 **Lipidomic analyses.** Lipids were extracted from *T. cruzi* samples using a modified Bligh & Dyer  
614 method (54, 55). Dried lipid extracts were reconstituted in 500 µL of 1:1 chloroform/methanol.  
615 For lipidomic analysis, a 10x dilution of the lipid extract was prepared in 95% acetonitrile/5%  
616 water with 5 mM ammonium acetate. Lipids were separated on a hydrophilic interaction liquid  
617 chromatography column (Waters CORTECS HILIC, 2.1 x 100 mm, 1.6 µm) using a 12 min  
618 gradient of 95% acetonitrile/5% water with 5 mM ammonium acetate and 50% acetonitrile/50%  
619 water with 5 mM ammonium acetate (56). IM-MS measurements were collected using a Waters  
620 Synapt XS in positive and negative ionization modes with data-independent MS/MS collection.  
621 Lock-mass correction, peak picking, alignment, and normalization was performed with  
622 Progenesis QI (Nonlinear Dynamics) and multivariate statistical analysis was performed in  
623 EZinfo (Umetrics). Lipid identifications were assigned first to the class level based on annotated  
624 HILIC retention times of yeast total lipid extract, followed by species level annotations against  
625 an in-house version of LipidPioneer using a mass accuracy threshold of 10 ppm (57). A 15 min  
626 isocratic reversed-phase liquid chromatography (Waters CORTECS C18, 2.1 x 100 mm, 1.7  
627 µm) method was used to confirm the identifications of cholesterol and ergosterol against  
628 reference standards (58). HPLC grade solvents (water, acetonitrile, methanol, and chloroform)  
629 and ammonium acetate were purchased from Thermo Fisher Scientific. Lipid reference  
630 standards were purchased from Avanti Lipids (Yeast Total Lipid Extract and d<sub>7</sub>-cholesterol) or  
631 Cayman Chemical (ergosterol).

632 **Author Contributions:** RDE, NMC, MGE, PC, PG, KB and KH designed and performed the  
633 experiments, analyzed the data and generated the figures. RDE and NMC wrote the manuscript  
634 with co-author input.

635  
636 **Declaration of Interests:** The authors declare no conflict of interest.

637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657

658 **References:**

- 659 1. Perez-Molina JA, Molina I. Chagas disease. *Lancet*. 2018;391(10115):82-94.
- 660 2. Mathers CD, Lopez AD, Murray CJL. The Burden of Disease and Mortality by Condition: Data,  
661 Methods, and Results for 2001. In: Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL, editors.  
662 Global Burden of Disease and Risk Factors. Washington (DC)2006.
- 663 3. Nickerson P, Orr P, Schroeder ML, Sekla L, Johnston JB. Transfusion-associated *Trypanosoma*  
664 *cruzi* infection in a non-endemic area. *Ann Intern Med*. 1989;111(10):851-3.
- 665 4. Pelosse P, Kribs-Zaleta CM. The role of the ratio of vector and host densities in the evolution of  
666 transmission modes in vector-borne diseases. The example of sylvatic *Trypanosoma cruzi*. *J Theor Biol*.  
667 2012;312:133-42.
- 668 5. Groom ZC, Protopapas AD, Zochios V. Tropical diseases of the myocardium: a review. *Int J Gen*  
669 *Med*. 2017;10:101-11.
- 670 6. Camandaroba EL, Reis EA, Goncalves MS, Reis MG, Andrade SG. *Trypanosoma cruzi*:  
671 susceptibility to chemotherapy with benznidazole of clones isolated from the highly resistant Colombian  
672 strain. *Rev Soc Bras Med Trop*. 2003;36(2):201-9.
- 673 7. Maguire JH. Treatment of Chagas' Disease--Time Is Running Out. *N Engl J Med*.  
674 2015;373(14):1369-70.
- 675 8. Sanchez-Valdez FJ, Padilla A, Wang W, Orr D, Tarleton RL. Spontaneous dormancy protects  
676 *Trypanosoma cruzi* during extended drug exposure. *Elife*. 2018;7.
- 677 9. Morgan GW, Hall BS, Denny PW, Carrington M, Field MC. The kinetoplastida endocytic  
678 apparatus. Part I: a dynamic system for nutrition and evasion of host defences. *Trends Parasitol*.  
679 2002;18(11):491-6.
- 680 10. Morgan GW, Hall BS, Denny PW, Field MC, Carrington M. The endocytic apparatus of the  
681 kinetoplastida. Part II: machinery and components of the system. *Trends Parasitol*. 2002;18(12):540-6.
- 682 11. Field MC, Carrington M. The trypanosome flagellar pocket. *Nat Rev Microbiol*. 2009;7(11):775-  
683 86.
- 684 12. Etheridge RD. Protozoan phagotrophy from predators to parasites: An overview of the enigmatic  
685 cytostome-cytopharynx complex of *Trypanosoma cruzi*. *J Eukaryot Microbiol*. 2022:e12896.
- 686 13. Flegontov P, Votypka J, Skalicky T, Logacheva MD, Penin AA, Tanifuji G, et al. Paratrypanosoma is  
687 a novel early-branching trypanosomatid. *Curr Biol*. 2013;23(18):1787-93.
- 688 14. Bretana A, O'Daly JA. Uptake of fetal proteins by *Trypanosoma cruzi* immunofluorescence and  
689 ultrastructural studies. *Int J Parasitol*. 1976;6(5):379-86.
- 690 15. de Souza W, de Carvalho TU, Benchimol M, Chiari E. *Trypanosoma cruzi*: ultrastructural,  
691 cytochemical and freeze-fracture studies of protein uptake. *Exp Parasitol*. 1978;45(1):101-15.
- 692 16. Alcantara CL, Vidal JC, de Souza W, Cunha-e-Silva NL. The three-dimensional structure of the  
693 cytostome-cytopharynx complex of *Trypanosoma cruzi* epimastigotes. *J Cell Sci*. 2014;127(Pt 10):2227-  
694 37.
- 695 17. Yubuki N, Leander BS. Evolution of microtubule organizing centers across the tree of eukaryotes.  
696 *Plant J*. 2013;75(2):230-44.
- 697 18. Chasen NM, Coppens I, Etheridge RD. Identification and Localization of the First Known Proteins  
698 of the *Trypanosoma cruzi* Cytostome Cytopharynx Endocytic Complex. *Front Cell Infect Microbiol*.  
699 2019;9:445.
- 700 19. Chasen NM, Etheridge MG, Etheridge RD. The Functional Characterization of TcMyoF Implicates  
701 a Family of Cytostome-Cytopharynx Targeted Myosins as Integral to the Endocytic Machinery of  
702 *Trypanosoma cruzi*. *mSphere*. 2020;5(3).
- 703 20. Urbina JA. Ergosterol biosynthesis and drug development for Chagas disease. *Mem Inst Oswaldo*  
704 *Cruz*. 2009;104 Suppl 1:311-8.

- 705 21. Lewit-Bentley A, Rety S. EF-hand calcium-binding proteins. *Curr Opin Struct Biol.* 2000;10(6):637-  
706 43.
- 707 22. Kobe B, Kajava AV. The leucine-rich repeat as a protein recognition motif. *Curr Opin Struc Biol.*  
708 2001;11(6):725-32.
- 709 23. Pennestri M, Melino S, Contessa GM, Casavola EC, Paci M, Ragnini-Wilson A, et al. Structural  
710 basis for the interaction of the myosin light chain Mlc1p with the myosin V Myo2p IQ motifs. *J Biol*  
711 *Chem.* 2007;282(1):667-79.
- 712 24. Wang W, Peng D, Baptista RP, Li Y, Kissinger JC, Tarleton RL. Strain-specific genome evolution in  
713 *Trypanosoma cruzi*, the agent of Chagas disease. *PLoS Pathog.* 2021;17(1):e1009254.
- 714 25. Teixeira SM, de Paiva RM, Kangussu-Marcolino MM, Darocha WD. Trypanosomatid comparative  
715 genomics: Contributions to the study of parasite biology and different parasitic diseases. *Genet Mol Biol.*  
716 2012;35(1):1-17.
- 717 26. Alonso VL. Ultrastructure Expansion Microscopy (U-ExM) in *Trypanosoma cruzi*: localization of  
718 tubulin isoforms and isotypes. *Parasitol Res.* 2022;121(10):3019-24.
- 719 27. Sinclair AN, Huynh CT, Sladewski TE, Zuromski JL, Ruiz AE, de Graffenried CL. The *Trypanosoma*  
720 *brucei* subpellicular microtubule array is organized into functionally discrete subdomains defined by  
721 microtubule associated proteins. *PLoS Pathog.* 2021;17(5):e1009588.
- 722 28. Alves AA, Alcantara CL, Dantas-Jr MVA, Sunter JD, De Souza W, Cunha ESNL. Dynamics of the  
723 orphan myosin MyoF over *Trypanosoma cruzi* life cycle and along the endocytic pathway. *Parasitol Int.*  
724 2022;86:102444.
- 725 29. Tomas AM, Miles MA, Kelly JM. Overexpression of cruzipain, the major cysteine proteinase of  
726 *Trypanosoma cruzi*, is associated with enhanced metacyclogenesis. *Eur J Biochem.* 1997;244(2):596-603.
- 727 30. Wang ZY, Wheeler RJ, Sunter JD. Lysosome assembly and disassembly changes endocytosis rate  
728 through the *Leishmania* cell cycle. *Microbiologyopen.* 2020;9(2).
- 729 31. Halliday C, Billington K, Wang Z, Madden R, Dean S, Sunter JD, et al. Cellular landmarks of  
730 *Trypanosoma brucei* and *Leishmania mexicana*. *Mol Biochem Parasitol.* 2019;230:24-36.
- 731 32. Greenberg MJ, Ostap EM. Regulation and control of myosin-I by the motor and light chain-  
732 binding domains. *Trends Cell Biol.* 2013;23(2):81-9.
- 733 33. Xia XM, Fakler B, Rivard A, Wayman G, Johnson-Pais T, Keen JE, et al. Mechanism of calcium  
734 gating in small-conductance calcium-activated potassium channels. *Nature.* 1998;395(6701):503-7.
- 735 34. Levay K, Slepak VZ. Regulation of Cop9 signalosome activity by the EF-hand Ca<sup>2+</sup>-binding protein  
736 tescalcin. *Journal of Cell Science.* 2014;127(11):2448-59.
- 737 35. Piazza M, Taiakina V, Dieckmann T, Guillemette JG. Structural Consequences of Calmodulin EF  
738 Hand Mutations. *Biochemistry.* 2017;56(7):944-56.
- 739 36. Pereira MG, Visbal G, Salgado LT, Vidal JC, Godinho JL, De Cicco NN, et al. *Trypanosoma cruzi*  
740 Epimastigotes Are Able to Manage Internal Cholesterol Levels under Nutritional Lipid Stress Conditions.  
741 *PLoS One.* 2015;10(6):e0128949.
- 742 37. Kirchoff LV, Hieny S, Shiver GM, Snary D, Sher A. Cryptic epitope explains the failure of a  
743 monoclonal antibody to bind to certain isolates of *Trypanosoma cruzi*. *J Immunol.* 1984;133(5):2731-5.
- 744 38. Kessler RL, Soares MJ, Probst CM, Krieger MA. *Trypanosoma cruzi* response to sterol  
745 biosynthesis inhibitors: morphophysiological alterations leading to cell death. *PLoS One.*  
746 2013;8(1):e55497.
- 747 39. Atcheson E, Hamilton E, Pathmanathan S, Greer B, Harriott P, Timson DJ. IQ-motif selectivity in  
748 human IQGAP2 and IQGAP3: binding of calmodulin and myosin essential light chain. *Biosci Rep.*  
749 2011;31(5):371-9.
- 750 40. Pathmanathan S, Hamilton E, Atcheson E, Timson DJ. The interaction of IQGAPs with calmodulin-  
751 like proteins. *Biochem Soc Trans.* 2011;39(2):694-9.

- 752 41. Nguyen H, Higuchi H. Motility of myosin V regulated by the dissociation of single calmodulin. *Nat*  
753 *Struct Mol Biol.* 2005;12(2):127-32.
- 754 42. Trybus KM, Gushchin MI, Lui H, Hazelwood L, Kremntsova EB, Volkmann N, et al. Effect of  
755 calcium on calmodulin bound to the IQ motifs of myosin V. *J Biol Chem.* 2007;282(32):23316-25.
- 756 43. Kremntsov DN, Kremntsova EB, Trybus KM. Myosin V: regulation by calcium, calmodulin, and  
757 the tail domain. *J Cell Biol.* 2004;164(6):877-86.
- 758 44. Vidal JC, Alcantara CL, W DES, Cunha ESNL. Lysosome-like compartments of *Trypanosoma cruzi*  
759 trypomastigotes may originate directly from epimastigote reservosomes. *Parasitology.* 2017;144(6):841-  
760 50.
- 761 45. Vanrell MC, Losinno AD, Cueto JA, Balcazar D, Fraccaroli LV, Carrillo C, et al. The regulation of  
762 autophagy differentially affects *Trypanosoma cruzi* metacyclogenesis. *PLoS Negl Trop Dis.*  
763 2017;11(11):e0006049.
- 764 46. Figueiredo RC, Steindel M, Soares MJ. The reservosomes of epimastigote forms of *Trypanosoma*  
765 *cruzi*: occurrence during in vitro cultivation. *Parasitol Res.* 1994;80(6):517-22.
- 766 47. Chiurillo MA, Lander N. The long and winding road of reverse genetics in *Trypanosoma cruzi*.  
767 *Microb Cell.* 2021;8(9):203-7.
- 768 48. Lander N, Li ZH, Niyogi S, Docampo R. CRISPR/Cas9-Induced Disruption of Paraflagellar Rod  
769 Protein 1 and 2 Genes in *Trypanosoma cruzi* Reveals Their Role in Flagellar Attachment. *MBio.*  
770 2015;6(4):e01012.
- 771 49. Huet D, Rajendran E, van Dooren GG, Lourido S. Identification of cryptic subunits from an  
772 apicomplexan ATP synthase. *eLife.* 2018;7.
- 773 50. Madeira F, Park YM, Lee J, Buso N, Gur T, Madhusoodanan N, et al. The EMBL-EBI search and  
774 sequence analysis tools APIs in 2019. *Nucleic Acids Res.* 2019;47(W1):W636-W41.
- 775 51. Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ. Jalview Version 2--a multiple  
776 sequence alignment editor and analysis workbench. *Bioinformatics.* 2009;25(9):1189-91.
- 777 52. McGinnis S, Madden TL. BLAST: at the core of a powerful and diverse set of sequence analysis  
778 tools. *Nucleic Acids Research.* 2004;32:W20-W5.
- 779 53. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein  
780 structure prediction with AlphaFold. *Nature.* 2021;596(7873):583-+.
- 781 54. Bligh EG, Dyer WJ. A Rapid Method of Total Lipid Extraction and Purification. *Canadian Journal of*  
782 *Biochemistry and Physiology.* 1959;37(8):911-7.
- 783 55. Havranek KE, Reyes Ballista JM, Hines KM, Brindley MA. Untargeted Lipidomics of Vesicular  
784 Stomatitis Virus-Infected Cells and Viral Particles. *Viruses.* 2021;14(1).
- 785 56. Hines KM, Herron J, Xu LB. Assessment of altered lipid homeostasis by HILIC-ion mobility-mass  
786 spectrometry-based lipidomics. *J Lipid Res.* 2017;58(4):809-19.
- 787 57. Ulmer CZ, Koelmel JP, Ragland JM, Garrett TJ, Bowden JA. LipidPioneer : A Comprehensive User-  
788 Generated Exact Mass Template for Lipidomics. *Journal of the American Society for Mass Spectrometry.*  
789 2017;28(3):562-5.
- 790 58. Herron J, Hines KM, Xu L. Assessment of Altered Cholesterol Homeostasis by Xenobiotics Using  
791 Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry. *Curr Protoc Toxicol.*  
792 2018;78(1):e65.
- 793  
794  
795  
796  
797  
798  
799



800 **Figure Legends**

801

802 **Figure 1 Schematic Summarizing the *Trypanosoma cruzi* SPC and Associated Myosins**

803 Four myosins are associated with the cytotostome cytopharynx complex (SPC). MyoF (*blue*) and  
804 MyoC (*green*) localize to the cytopharynx portion of the SPC, while MyoB (*magenta*) and MyoE  
805 (*orange*) localize to the pre-oral ridge.

806 **Figure 2 Double Knockouts for MyoF and MyoC Show a Synergistic Loss of SPC**  
807 **Endocytosis.**

808 **A.** Scheme for CRISPR/Cas9 gene deletion and complementation of MyoC in both Y-Strain and  
809  $\Delta MyoF$  (*gray tint*) backgrounds. Location of primers used for PCR verification of loci  
810 modifications are annotated (*green and blue arrows*).

811 **B.** PCR amplification with MyoC screening primers (*green arrows in A*) shows replacement of  
812 both Parental loci (high-molecular-weight (MW) band) with the blasticidin resistance gene (low-  
813 MW band) in  $\Delta MyoC$  and  $\Delta MyoF\Delta MyoC$  ( $\Delta F\Delta C$ ) mutants. The higher MW PCR product  
814 amplified from the  $\Delta MyoF\Delta MyoC::MyoC-Ty$  ( $\Delta F\Delta C::C-Ty$ ) mutants, shows correct insertion into  
815 the original  $\Delta MyoC$  locus.

816 **C.** PCR amplification with MyoF screening primers (*blue arrows in A*) shows replacement of the  
817 MyoF loci (high-MW band) with the blasticidin resistance cassette (low-MW band) in both the  
818 single and double knockout mutants.

819 **D.** IFA of MyoC-Ty complemented epimastigotes shows localization to the distinct linear  
820 structure of the SPC.

821 **E.**  $\Delta MyoC$  epimastigotes (*green*) showed no significant reduction in SPC endocytic rate,  
822 whereas  $\Delta MyoF$  (*blue*) epimastigotes show an endocytic rate reduction as previously described.  
823 Treatment with the actin polymerization inhibitor Cytochalasin D during the assay is used as a  
824 negative control for feeding assays throughout this manuscript (*grey*).

825 **F.**  $\Delta F\Delta C$  mutants (*red*) show a loss of detectable endocytosis, in contrast with the partial  
826 endocytic rate reduction seen in the  $\Delta MyoF$  (*blue*) background. Complementation with MyoC-Ty  
827 in  $\Delta F\Delta C::C-Ty$  mutants (*yellow*) resulted in a similar endocytic rate to that seen in the  $\Delta MyoF$   
828 single knockout background (*blue*).

829 **G.** Quantification of endocytic rate in mutants shown in panels E and F show the synergy  
830 between MyoF and MyoC deletion in reducing SPC endocytosis.

831 Scale bar 2  $\mu\text{m}$ .

832 **Figure 3 A Myosin Associated Protein (MyAP) Localizes to the SPC Microtubules**

833 **A.** Oriole-stained gel (*top*) showing the eluate from  $\alpha Ty$  co-IP of MyoF-mNeon-Ty (*arrow*)  
834 overexpressing parasites. Table (*bottom*) shows mass spectrometry results from MyoF pulldown  
835 and the two identified isoforms of MyAP.

836 **B.** MyAP AlphaFold predicted structure of (TcCLB.508479.180) (*top*) and predicted domains  
837 (*bottom*) on an amino acid scale line. Predicted leucine rich repeat (*green*), coiled coil (*yellow*),  
838 and EF-hand domains (*blue*) are shown. Also shown are the amino acids found only in the

839 MyAP **b** isoform (*red vertical line*) and the antigenic region used for MyAP antibody generation  
840 (*pink horizontal line*).

841 **C.** Fluorescence microscopy of a transiently overexpressed MyAP-mNeon showing localization  
842 to the typical SPC linear structure in epimastigotes.

843 **D.** Immunofluorescence assay in MyoF-mNeon expressing epimastigotes showing co-  
844 localization between the SPC myosin MyoF-mNeon and  $\alpha$ MyAP mouse antibody (1:200).

845 **E.** Ultrastructure expansion microscopy reveals that MyAP (*top*), MyoF (*middle*), and MyoC  
846 (*bottom*) all localize to the SPC associated microtubules labelled by TAT1.

847 **F.** Bootstrapped consensus tree shows the relationship between *T. cruzi* MyAP and its orthologs  
848 in a diverse range of protozoa including ciliates (*red box*) and other kinetoplastids (*blue box*). An  
849 ortholog from *Vitrella brassicaformis* was chosen as the outgroup.

850 Scale bars 2  $\mu$ m (C, D) and 20  $\mu$ m (E).

#### 851 **Figure 4 Deletion of MyAP Produces an Endocytic-Null Phenotype in Epimastigotes.**

852 **A.** Scheme for the CRISPR/Cas9 gene deletion and complementation of MyAP. Location of  
853 primers used for PCR verification are also shown (*arrows*).

854 **B.** PCR amplification of the MyAP genomic locus shows replacement of both Parental loci (high-  
855 molecular-weight (MW) band) with the blasticidin resistance gene (low-MW band) in  $\Delta$ MyAP  
856 mutants. Complementation with MyAP-Ty into the original MyAP locus ( $\Delta$ MyAP::MyAP-Ty) is  
857 demonstrated by the high-MW band.

858 **C.** Western blot of Parental,  $\Delta$ MyAP, and  $\Delta$ MyAP::MyAP-Ty epimastigote lysates using  $\alpha$ MyAP  
859 mouse antibody (1:500) showing the successful deletion and restoration of MyAP protein.

860 **D.** Flow cytometry analysis of fluorescent BSA fed epimastigotes shows an absence of  
861 detectable endocytosis in  $\Delta$ MyAP epimastigotes (*orange*) similar to the Cytochalasin D treated  
862 negative control (*gray*). This endocytic defect is rescued in the  $\Delta$ MyAP::MyAP-Ty  
863 complemented mutants (*magenta*).

864 **E.** Quantification of three biological replicates of feeding assays, as shown in panel D,  
865 demonstrates ablation of endocytic activity in  $\Delta$ MyAP epimastigotes and its rescue upon  
866 complementation ( $\Delta$ MyAP::MyAP-Ty).

867 **F.** Expression of MyoF-mNeon (*top*) and MyoC-mNeon (*bottom*) in Parental,  $\Delta$ MyAP, and  
868  $\Delta$ MyAP::MyAP-Ty epimastigotes shows that MyoF and MyoC are mislocalized to the cytosol in  
869 the  $\Delta$ MyAP mutants (*middle*). Localization to the SPC is rescued upon complementation of  
870 MyAP ( $\Delta$ MyAP::MyAP-Ty, *right*).

871 Scale bars 2  $\mu$ m.

#### 872 **Figure 5 The Predicted Calcium Binding EF-hand Structure of MyAP is Essential for** 873 **Endocytic Activity.**

874 **A.** Scheme of MyAP showing the predicted Leucine Rich Repeat (*green*) and paired EF-hand  
875 domains (*blue*) chosen for removal from the MyAP coding sequence prior to complementation  
876 into  $\Delta$ MyAP epimastigotes.

877 **B.** PCR amplification of the MyAP locus showing complementation of the various MyAP genes  
878 that were altered via mutagenesis.

879 **C.** Western blot with  $\alpha$ MyAP shows that the various MyAP versions are being expressed and  
880 translated in the complemented mutant epimastigotes.

881 **D.** Flow cytometry analysis of fluorescent BSA fed epimastigotes shows a negligent restoration  
882 of endocytic activity in  $\Delta$ MyAP epimastigotes complemented with MyAP lacking the EF-hand  
883 structure ( $\Delta$ MyAP::*MyAP-EFh-Ty*) (*blue*). In contrast, normal endocytic activity was observed in  
884 epimastigotes complemented with MyAP lacking the LRR domain ( $\Delta$ MyAP::*MyAP-LRR-Ty*)  
885 (*green*).

886 **E.** Quantification of three biological replicates of feeding assays, as shown in panel D, shows  
887 the failed restoration of endocytic rate in parasites complemented with *MyAP-EFh-Ty* (*blue*)  
888 when compared to those complemented with *MyAP-LRR* (*green*) or wild type *MyAP-Ty*.  
889 (*magenta*).

890 **F.** Unlike what was observed in the  $\Delta$ MyAP endocytic-null mutants, MyoF-mNeon localizes  
891 normally to the SPC in both  $\Delta$ MyAP::*MyAP-LRR-Ty* and  $\Delta$ MyAP::*MyAP-EFh-Ty* epimastigotes.

892 Scale bars 2  $\mu$ m.

### 893 **Figure 6 Deletion of MyAP Results in Altered Reservosomes and Defects in Sterol** 894 **Accumulation**

895 **A.** Scanning electron micrographs reveal that the endocytic-null phenotype of  $\Delta$ MyAP  
896 epimastigotes is not caused by the lack of a cytostome opening, as it can be observed in both  
897 the Parental and  $\Delta$ MyAP epimastigotes. Scale bars 2  $\mu$ m.

898 **B.** Transmission electron microscopy of Parental Y Strain epimastigotes (*left*) shows electron  
899 lucent structures in the pre-lysosomal reservosomes that have the typical appearance of typical  
900 of lipid inclusions. These inclusions are absent in the uniform electron dense reservosomes of  
901  $\Delta$ MyAP epimastigotes (*middle*) and their presence is rescued upon complementation (*right*).  
902 Scale bars 0.5  $\mu$ m.

903 **C.** Lipidomic analysis of the sterol content in  $\Delta$ MyAP epimastigotes (*orange*) shows a  
904 dramatically reduced cholesterol content (*right*) compared to the Parental (*black*) that is restored  
905 upon complementation (*magenta*). No such difference is observed in the levels of endogenously  
906 synthesized ergosterol (*left*).

### 907 **Supplementary Figure 1 Endocytic-Null Mutants Do Not Show a Significant Growth** 908 **Defect in Culture**

909 **A, B.** Similar growth rate is seen in both cumulative (A) and absolute (B) growth rate assays of  
910 MyoF and MyoC knockout and complement mutant epimastigotes.

911 **C, D.** Likewise, no significant growth rate reduction can be seen in the endocytic-null  $\Delta$ MyAP or  
912  $\Delta$ MyAP::*MyAP-EFh* epimastigotes in either cumulative (C) or absolute (D) growth rate assays.

### 913 **Supplementary Figure 2 Deletion of MyAP Does Not Alter the Localization of the Preoral** 914 **Ridge Myosins**

915 Preoral ridge myosins MyoB (*left*) and MyoE (*right*) maintain their normal localization the pre-  
916 oral ridge in  $\Delta MyAP$  epimastigotes.

917 **Supplementary Figure 3 Additional Expansion Microscopy Images Showing Microtubule**  
918 **Localization of MyoF, MyoC, and MyAP**

919 **A, B, C.** Additional supporting expansion microscopy showing TAT1 (*red*) labelled microtubule  
920 localization of MyAP-Ty, MyoF-Ty, and MyoC-Ty as in Figure 3 Panel E.

921 **D.** Negative control showing background Ty labeling in Parental line.

922 **E, F.** Expansion ultrastructure microscopy images showing TAT1 labeling of microtubules in  
923  $\Delta MyAP$  epimastigotes. In panel F, both the microtubule quartet (*red arrowhead*) and triplet  
924 (*green arrowhead*) can be clearly differentiated, suggesting there is no disruption in microtubule  
925 formation.

926 **Supplementary Figure 4 MyAP is Enriched in the Detergent Insoluble Cytoskeletal**  
927 **Fraction**

928 Immunoblot of detergent extracted lysates show an enrichment of MyAP in the detergent  
929 resistant cytoskeletal fraction of the Parental and  $\Delta MyAP::MyAP-Ty$  lines (*top*). Cruzipain was  
930 used as a marker for the detergent soluble fraction (S). The total absence of cruzipain labeling  
931 in the detergent insoluble cytoskeletal fraction (P) is evidence of a clean fraction (*middle*). Total  
932 protein stain from the BioRad Stain-Free gel used for this blot is also shown (*bottom*).

933 **Supplementary Figure 5 T-coffee Multiple Sequence Alignment and Gene IDs Used for**  
934 **Tree in Figure 3**

935 **Supplementary Figure 6 Localization of MyAP in Strains Used in This Study**

936 **A.** Immunofluorescence assay of MyAP using the  $\alpha MyAP$  mouse antibody (1:200) in the  
937 Parental strain (green). ConA lectin surface staining of epimastigotes in red. DAPI in blue.

938 **B.** Immunofluorescence assay of MyAP using the  $\alpha MyAP$  mouse antibody (1:200) in the  $\Delta MyAP$   
939 strain (green). ConA lectin surface staining of epimastigotes in red. DAPI in blue.

940 **C.** Immunofluorescence assay of MyAP using the  $\alpha MyAP$  mouse antibody (1:200) in the  
941  $\Delta MyAP::MyAP-Ty$  strain (green). ConA lectin surface staining of epimastigotes in red. DAPI in  
942 blue.

943 **D.** Immunofluorescence assay of MyAP using the  $\alpha MyAP$  mouse antibody (1:200) in the  
944  $\Delta MyAP::MyAP\Delta LRR-Ty$  strain (green). ConA lectin surface staining of epimastigotes in red.  
945 DAPI in blue.

946 **E.** Immunofluorescence assay of MyAP using the  $\alpha MyAP$  mouse antibody (1:200) in the  
947  $\Delta MyAP::MyAP\Delta EFh-Ty$  strain (green). ConA lectin surface staining of epimastigotes in red.  
948 DAPI in blue.

949 **F.** Immunofluorescence assay of MyAP using the  $\alpha MyAP$  mouse antibody (1:200) in the  $\Delta MyoC$   
950 strain (green). ConA lectin surface staining of epimastigotes in red. DAPI in blue.

951 **G.** Immunofluorescence assay of MyAP using the  $\alpha MyAP$  mouse antibody (1:200) in the  $\Delta MyoF$   
952 strain (green). ConA lectin surface staining of epimastigotes in red. DAPI in blue.

953 **H.** Immunofluorescence assay of MyAP using the  $\alpha$ MyAP mouse antibody (1:200) in the  
954  $\Delta$ MyoF:: $\Delta$ MyoC strain (green). ConA lectin surface staining of epimastigotes in red. DAPI in  
955 blue.

956 Scale bars 2  $\mu$ m.

957 **Supplementary Figure 7 Endocytosis is Not Disrupted by the Mutagenesis of Predicted**  
958 **Calcium Binding Residues in MyAP**

959 **A.** AlphaFold structure showing three aspartic acid residues that we identified as potentially  
960 essential for calcium binding in the EF-hand structure, with D616 being the most promising  
961 candidate.

962 **B.** Expanded gel (from Figure 5 Panel B) shows PCR amplification of the MyAP locus and  
963 successful heterozygous complementation of the aspartic acid to alanine mutagenized versions  
964 of MyAP (*blue dotted rectangle*) into the original locus (*faint high-MW band*).


965 **C.** Expanded immunoblot (from Figure 5 Panel C) probed with  $\alpha$ MyAP shows successful  
966 expression of the mutagenized aspartic acid versions of MyAP (*blue dotted rectangle*).

967 **D.** Quantification of three fluorescent BSA feeding assays shows that all three mutagenized  
968 versions of MyAP (*yellow, orange, dark orange*) were capable of fully rescuing endocytic activity  
969 in the  $\Delta$ MyAP background.


970 **Supplementary Figure 8 Principal Component Analysis of Mass Spectrometry-Based**  
971 **Lipidomics Analysis**

972 **A.** The sample type (media versus *T. cruzi*) is separated along principal component 1 (PC1).  
973 The separation along PC2 indicates that the Parental and Complement share similarities with  
974 the Media, whereas the KO is distinct from those three. Principal-component analysis of  
975 lipidomic data reveals that *T. cruzi* strains lacking the ability to endocytose ( $\Delta$ MyAP) display an  
976 alteration of the lipid profile of parasites grown in LIT/LDNT (Media) as compared to those  
977 strains able to carry out SPC mediated nutrient uptake (Parental and  $\Delta$ MyAP::*MyAP-Ty*  
978 complemented lines) as highlighted in the blue dotted line rectangle.


979




MyoF




MyoC










MyoB





MyoE








- MyoF
- MyoC
- MyoB
- MyoE

**A****B****C****D****E****F****G**





**A****B****C****D****E****F**